Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Seoul says sorry after unapproved drone flights into North Korea - 2One perk to marrying Richard Marx later in life? 'We don't have time' for stupid arguments, says Daisy Fuentes.
- 3‘The White Lotus’ sparked online interest in risky anxiety pills, study says
- 4An Extended time of Self-Reflection: Self-awareness through Journaling
- 5Nations for Rock Climbing
- Instructions to Perceive and Grasp the Early Side effects of Cellular breakdown in the lungs
- Tuesday, April 7. Russia’s War On Ukraine: News And Information From Ukraine
- The Best Computer games for Multiplayer Fun
- Find the Insider facts of Viable Advertising: Building a Positive Brand Picture
- Find the Mysteries of Powerful Using time productively: Augmenting Efficiency and Proficiency
- Everything to know about NASA's moon mission launching this week
- Becoming the best at Discussion: Individual Procedures
- Taylor Swift's 'The End of an Era' docuseries: Everything you need to know, plus how to watch for less
- Day to day Temporary Positions That Compensate Fairly in the US
